Inhibitor of vascular endothelial cell growth factor

Details Inhibitor of vascular endothelial cell growth factor Inhibitor of vascular endothelial cell growth factor

2009-02-06

2011-10-11

Saoud, Christine J (Department: 1647)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

C530S350000

Reexamination Certificate

active

08034772

ABSTRACT:
The vascular endothelial cell growth factor (VEGF) inhibitors of the present invention are naturally occurring or recombinantly engineered soluble forms with or without a C-terminal transmembrane region of the receptor for VEGF, a very selective growth factor for endothelial cells. The soluble forms of the receptors will bind the growth factor with high affinity but do not result in signal transduction. These soluble forms of the receptor bind VEGF and inhibit its function.

REFERENCES:
patent: WO 92/14748 (1992-09-01), None
patent: WO 94/10202 (1994-05-01), None
patent: WO 94/11499 (1994-05-01), None
Conn, G. et al., “Amino acid and cDNA sequences of a vascular endothelial cell mitogen that is homologous to platelet-derived growth factor”, Proc., Natl. Acad. Sci. USA, 1990, vol. 87, pp. 2628-2632.
Ferrara, N. et al., “Pituitary folllicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells”, Biochem. and Biophys. Res. Comm., 1989, vol. 161, pp. 851-858.
Gospodarowicz, D. et al., “Isolation and characterization of a vascular endothelial cell mitogen produced by pituitary-derived folliculo stellate cells”, Proc. Natl. Acad. Sci. USA, 1989, vol. 86, pp. 7311-7315.
Connolly, D. et al., “Vascular permeability factor, an endothelial cell mitogen related to PDFG”, Science, 1989, vol. 246, pp. 1309-1312.
DeVries, C. et al., “The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor”, Science, 1992, vol. 255, pp. 989-991.
Terman, B. et al., “Identification of a new endothelial cell growth factor receptor tyrosine kinase”, Oncogen, 1991, vol. 6, pp. 1677-1683.
Terman, B. et al., “Identification of the KDR tyrosine kinase as a receptor for vascular endothelial cell growth factor”, Biochem. and Biophys. Res. Comm., 1992, vol. 187, pp. 1579-1586.
Shibuya, M. et al., “Nucleotide sequence and expression of a novel human receptor-type tyrosine kinase gene (flt) closely related to fms family”, Oncogen, 1990, vol. 5, pp. 519-524.
Duan, D. et al., “A functional soluble extracellular region of the platelet-derived growth factor (PDGF) B-receptor antagonizes PDGF-stimulated responses”, The J. of Biol. Chem., 1991, Vo. 266, pp. 413-418.
Hoshi, H. et al., “Brain- and liver cell-derived factors are required for growth of human endothelial cells in serum-free culture”, Proc. Natl. Acad. Sci. USA, 1984, vol. 81, pp. 6413-6417.
Sanger, F. et al., “DNA sequencing with chain-terminating inhibitors”, Proc. Natl. Sci. USA, 1977, vol. 74, pp. 5463-5467.
Feinberg A. et al., “A technique for radiolabeling DNA restriction endonuclease fragments to high specific activity”, Anal. Biochem., 1983, vol. 132, pp. 6-13.
Hunter, W. et al., “Preparation of iodine-131 labelled human growth hormone of high specific activity”, Nature, 1962, vol. 194, pp. 495-496.
Scatchard, G., “The attractions of proteins for small molecules and ions”, Annals NY Acad. of Sci., 1949, vol. 51, pp. 660-672.
Bikfalvi A. et al., “Interaction of vasculotropin/vascular endothelial cell growth factor with human umbilical vein endothelial cells: binding, internalization, degradation, and biological effects”, J. of Cell. Phys., 1991, vol. 149, pp. 50-59.
Olsson, I. et al., “The receptors of regulatory molecules of hematopoiesis”, Eur. J. Haematol., 1992, vol. 48, pp. 1-9.
Kim, K. et al., “The vascular endothelial growth factor proteins: Identification of biologically relevant regions by neutralizing monoclonal antibodies”, Growth Factors, 1992, vol. 7, pp. 53-64.
Ueno, H. et al., “Inhibition of PDGF B receptor signal transduction by coexpression of a truncated receptor”, Science, 1991, vol. 252, pp. 844-848.
Maliszewski, C. et al., “Cytokine receptors and B cell functions I. Recombinant soluble receptors specificlaly inhibit IL-1 and IL-4-induced B cell activities in vitro”, J. of Immunology, 1990, vol. 144, pp. 3028-3033.
Kendall, R. et al., “Inhibition of vascular endothelial cell growth factor activity by an endogenously encoded soluble receptor”, Proc. Natl. Acad. Sci. USA, vol. 90, pp. 10705-10709, 1993.
Millauer, B. et al., “Glioblastoma growth inhibited in vivo by a dominant-negative Flk-1 mutant”, Nature, 1994, vol. 367, pp. 576-579.
Millauer, B. et al., “High affinity VEGF binding and development expression suggest Flk-1 as a major regulator of vasculogenesis and angiogenesis”, Cell, 1993, vol. 72, pp. 835-836.

Affiliated with

Also associated with

Rating

Inhibitor of vascular endothelial cell growth factor does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Inhibitor of vascular endothelial cell growth factor, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Inhibitor of vascular endothelial cell growth factor will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4299978